Evidence map›Paper›PMID 28938946›Full record

ArticleKidney international2017

Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy.

Nicholas Chun, Christina M Wyatt, John C He

Abstract readComment
PubMed Publisher
In one paragraph

Article in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Nicholas ChunDepartment of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Christina M WyattDepartment of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
John C HeDepartment of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a recent paper in Nature Medicine, Qi et al. set out to identify protective pathways in patients with longstanding diabetes who do not develop diabetic nephropathy. Unbiased proteomic analysis of kidney tissue identified a unique protein signature in unaffected individuals. Studies in vitro and in murine models identified the highly upregulated glycolytic enzyme pyruvate kinase M2 as a potential therapeutic target to prevent or treat diabetic nephropathy.

Indexed as

Diabetic NephropathiesAnimalsHumansKidney GlomerulusMiceMitochondriaProteomicsPyruvate KinasePyruvate Kinasediabetic nephropathymitochondriaoxidative stresspodocyteproteomic analysis

Identifiers

PMID28938946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.